LM against CYP-2C19 are different from the previously described LM autoantibodies directed against CYP-1A2, considered hallmark of AIH in children affected by Type 1 Autoimmune Polyglandular Syndrome (APS 1) [9–16]. The gene discussed is CYP1A2; the disease is autoimmune polyendocrine syndrome type 1.